1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €41.43 (+37.64%). The median is €41.43 (+37.64%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 300.54M | 17.30% |
| Gross profit | 257.61M | 21.45% |
| Net profit | 106.9M | 599.98% |
| EBITDA | 141.95M | 104.03% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.76B |
Number of shares | 124.77M |
52-week high/low | €36.95 - €19.18 |
| Dividends | No |
Beta | 1.03 |
P/E ratio | 12.28 |
PEG ratio | 0.07 |
P/B ratio | -21.01 |
P/S ratio | 3.27 |
Company profile
| Name | INDIVIOR PHARMACEUTICALS INC NPV |
| CEO | Joseph J. Ciaffoni |
| Employees | 833 |
Deep Dive
Discover assets
Shareholders of INDIVIOR PHARMACEUTICALS INC NPV also invest in the following assets
